運輸署批227條巴士路線調整服務
運輸署公布,因應實施多項措施以阻止2019冠狀病毒病在社區傳播,專營巴士的乘客量受到影響而大幅減少,運輸署批准部分巴士路線調整服務,涉及227條路線,有效期7天。
其中九巴調整班次的路線數目為110,新巴為48,城巴為56,九巴/新巴聯營為6,九巴/城巴聯營為6,新大嶼山巴士為1。
獲批准調整班次的路線,在晚上10時前(包括繁忙時段及非繁忙時段)的班次最多延長不超過5分鐘,而於晚上10時後的班次則最多延長不超過10分鐘,惟延長後的班次間距時間不會超過30分鐘。另有4條乘客量嚴重偏低的路線,獲准暫停服務或調整服務時間。
運輸署已要求巴士公司密切留意相關路線的乘客需求變化,視乎情況在有需要時加強服務,在資源許可下讓乘客有較多乘車空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.